Insys Therapeutics price target raised to $27 from $18 at JMP Securities

theflyonthewall.com

After Insys reported stronger than expected Q2 results, JMP Securities raised its target on the company based on the continued strong performance of its cancer pain management treatment, Subsys. The firm reiterates an Outperform rating on the stock.

View Comments